Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants
Yoshitomo Morinaga, Hideki Tani, Yasushi Terasaki, Satoshi Nomura, Hitoshi Kawasuji, Takahisa Shimada, Emiko Igarashi, Yumiko Saga, Yoshihiro Yoshida, Rei Yasukochi, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Takashi Fujimura, Yoichi Ishida, Kazunori Oishi, Yoshihiro Yamamoto
doi: https://doi.org/10.1101/2021.05.25.21257828
Yoshitomo Morinaga
aDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Hideki Tani
aDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
bDepartment of Virology, Toyama Institute of Health, Toyama, Japan
Yasushi Terasaki
cToyama City Hospital, Toyama, Japan
Satoshi Nomura
cToyama City Hospital, Toyama, Japan
Hitoshi Kawasuji
dDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Takahisa Shimada
aDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
bDepartment of Virology, Toyama Institute of Health, Toyama, Japan
Emiko Igarashi
bDepartment of Virology, Toyama Institute of Health, Toyama, Japan
Yumiko Saga
aDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
bDepartment of Virology, Toyama Institute of Health, Toyama, Japan
Yoshihiro Yoshida
aDepartment of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Rei Yasukochi
dDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Makito Kaneda
dDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Yushi Murai
dDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Akitoshi Ueno
dDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Yuki Miyajima
dDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Yasutaka Fukui
dDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Kentaro Nagaoka
dDepartment of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
Chikako Ono
eLaboratory of Virus Control, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan
fLaboratory of Virus Control, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan
Yoshiharu Matsuura
eLaboratory of Virus Control, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan
fLaboratory of Virus Control, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan
Takashi Fujimura
cToyama City Hospital, Toyama, Japan
Yoichi Ishida
cToyama City Hospital, Toyama, Japan
Kazunori Oishi
gToyama Institute of Health, Toyama, Japan
Yoshihiro Yamamoto
eLaboratory of Virus Control, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article usage
Posted May 27, 2021.
Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants
Yoshitomo Morinaga, Hideki Tani, Yasushi Terasaki, Satoshi Nomura, Hitoshi Kawasuji, Takahisa Shimada, Emiko Igarashi, Yumiko Saga, Yoshihiro Yoshida, Rei Yasukochi, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Takashi Fujimura, Yoichi Ishida, Kazunori Oishi, Yoshihiro Yamamoto
medRxiv 2021.05.25.21257828; doi: https://doi.org/10.1101/2021.05.25.21257828
Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants
Yoshitomo Morinaga, Hideki Tani, Yasushi Terasaki, Satoshi Nomura, Hitoshi Kawasuji, Takahisa Shimada, Emiko Igarashi, Yumiko Saga, Yoshihiro Yoshida, Rei Yasukochi, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Takashi Fujimura, Yoichi Ishida, Kazunori Oishi, Yoshihiro Yamamoto
medRxiv 2021.05.25.21257828; doi: https://doi.org/10.1101/2021.05.25.21257828
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (669)
- Anesthesia (181)
- Cardiovascular Medicine (2650)
- Dermatology (223)
- Emergency Medicine (400)
- Epidemiology (12234)
- Forensic Medicine (10)
- Gastroenterology (760)
- Genetic and Genomic Medicine (4109)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2661)
- Health Policy (1005)
- Hematology (364)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (439)
- Neurology (3890)
- Nursing (210)
- Nutrition (578)
- Oncology (2037)
- Ophthalmology (585)
- Orthopedics (241)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (452)
- Public and Global Health (6536)
- Radiology and Imaging (1407)
- Respiratory Medicine (871)
- Rheumatology (410)
- Sports Medicine (343)
- Surgery (450)
- Toxicology (53)
- Transplantation (185)
- Urology (166)